Cardiac Sarcoidosis: HRS Diagnostic Criteria, Imaging, and Immunosuppression

Cardiac Sarcoidosis: HRS Diagnostic Criteria, Imaging, and Immunosuppression

CardiologyGranulomatous MyocarditisFDG-PET + CMRHRS 2014

Executive Summary

Cardiac sarcoidosis (CS) is a non-caseating granulomatous infiltration of the myocardium that causes conduction disease, ventricular arrhythmias, and dilated cardiomyopathy. It complicates 20-30% of systemic sarcoidosis on advanced imaging but is clinically apparent in only 5%, often presenting in patients aged 25-60 with unexplained high-grade AV block, sustained ventricular tachycardia, or non-ischemic cardiomyopathy. The thinned, scarred basal interventricular septum is the morphologic signature. Diagnosis follows the HRS 2014 criteria combining clinical features with histologic confirmation (preferably extracardiac) and advanced imaging — cardiac MRI with late gadolinium enhancement for fibrosis, FDG-PET (after dedicated cardiac sarcoid prep) for active inflammation. Endomyocardial biopsy yields only 20-30% even when image-guided due to patchy granuloma distribution. Treatment combines glucocorticoids (prednisone 0.5-1 mg/kg/d, taper over 6-12 months) with steroid-sparing agents (methotrexate, azathioprine) and selective ICD implantation following HRS 2014 indications. Refractory disease may require infliximab. Five-year survival approaches 90% with early diagnosis and adequate immunosuppression but falls to 60% with severe LV dysfunction at presentation.

25%Subclinical involvement (autopsy)
5%Clinically apparent CS
85%5-yr survival if EF preserved
60%5-yr survival if EF <35%

S1. Pathophysiology and Clinical Phenotype

Cardiac sarcoidosis is the cardiac manifestation of systemic sarcoidosis, an immune-mediated multisystem disease driven by exaggerated Th1/Th17 cellular response to yet-unidentified antigens. Non-caseating granulomas — clusters of CD4+ T cells, macrophages, and multinucleated giant cells — infiltrate the myocardium with a characteristic predilection for the basal interventricular septum, free wall of the left ventricle, papillary muscles, and the conduction system. The granulomas progress through phases of active inflammation (edema, FDG-avid lesions on PET), fibrosis (replacement scar visible on CMR late gadolinium enhancement), and aneurysmal thinning. This patchy, transmural-or-not distribution explains both the low yield of endomyocardial biopsy and the strong dependence on advanced imaging for diagnosis.

Three classic clinical syndromes

SyndromeMechanismClinical featuresRisk implication
Conduction diseaseGranuloma in basal septum disrupts AV node and proximal conductionUnexplained 2nd or 3rd degree AV block in patient aged <60; bundle branch block; sinus node dysfunction30-50% of CS presentations; mandates CS workup before pacemaker placement
Ventricular arrhythmiaScar-related re-entry around fibrotic granulomasSustained monomorphic VT (often multiple morphologies, atypical for ischemic VT), VF, sudden cardiac death20-30% of CS; first manifestation in 10-20%; high SCD risk
Cardiomyopathy / heart failureDiffuse granulomatous infiltration → systolic dysfunction; LV thinning, dilation; rarely diastolic-restrictive patternNYHA II-IV heart failure, LV dilation, segmental wall motion abnormality (often basal septum thinning), apical aneurysm20-40% of CS; LVEF strongly prognostic

Less common presentations include atrial arrhythmias (atrial fibrillation in 15-20%), syncope of unclear etiology, valvular regurgitation from papillary muscle involvement, and isolated pericardial effusion. Importantly, isolated cardiac sarcoidosis without extracardiac disease occurs in 25-30% of patients and is harder to diagnose because it lacks the supporting context of obvious pulmonary or skin sarcoidosis.

Pearl: Any patient under age 60 with unexplained Mobitz II or third-degree AV block should be evaluated for cardiac sarcoidosis BEFORE permanent pacemaker implantation. Implanting a standard pacemaker first commits the patient to lifelong device therapy without addressing underlying granulomatous inflammation, and misses the window for ICD upgrade if VT subsequently emerges. Workup adds days, not weeks, and changes management.

S2. HRS 2014 Diagnostic Criteria

The Heart Rhythm Society 2014 expert consensus established two parallel diagnostic pathways: histological (definitive) and clinical (probable). The Japanese Circulation Society 2016 criteria are similar but include “isolated cardiac sarcoidosis” as a recognized entity with imaging-only criteria. Both frameworks remain in use; HRS 2014 is the dominant reference in North American practice.

Pathway 1: Histological diagnosis

Demonstration of non-caseating granuloma on endomyocardial biopsy in a patient without alternative explanation establishes definite cardiac sarcoidosis. Sensitivity of EMB is poor (20-30% even with image guidance) due to patchy distribution. A positive EMB obviates the need for clinical pathway analysis.

Pathway 2: Clinical diagnosis (probable cardiac sarcoidosis)

Requires ALL of:

  1. Histological confirmation of extracardiac sarcoidosis (mediastinal/hilar lymph node, lung, skin)
  2. One or more of the following clinical features, otherwise unexplained:
    • Cardiomyopathy or heart failure responsive to steroid or immunosuppression
    • Unexplained reduced LVEF (<40%)
    • Unexplained sustained (greater than 30 sec) ventricular tachycardia
    • Mobitz II or third-degree AV block
    • Patchy uptake on dedicated cardiac PET (focal-on-diffuse pattern)
    • Late gadolinium enhancement on CMR (typical pattern)
    • Positive gallium uptake (rarely used now; superseded by PET)
  3. Other causes of cardiomyopathy or arrhythmia have been reasonably excluded (coronary disease, hypertension, infiltrative diseases like amyloidosis, hypertrophic cardiomyopathy)
Diagnostic strategy in practice: The most efficient pathway is (a) confirm extracardiac sarcoidosis by transbronchial lymph node biopsy or skin biopsy, then (b) obtain CMR and FDG-PET to demonstrate cardiac involvement. EMB is reserved for isolated CS without accessible extracardiac biopsy site, and for cases where alternative diagnoses (giant cell myocarditis, amyloidosis) must be definitively excluded.

S3. Advanced Imaging: CMR and FDG-PET

CMR and FDG-PET answer different questions and are complementary, not interchangeable. CMR maps fibrosis (chronic damage) with late gadolinium enhancement and identifies edema (acute inflammation) on T2-weighted/T2 mapping. FDG-PET maps active glycolysis in inflammatory cells (macrophages, lymphocytes) and is the only modality that confirms ongoing inflammation amenable to immunosuppression. Combined CMR + PET reaches sensitivity 90% and specificity 85% for clinically significant CS.

Cardiac MRI: typical findings

  • Late gadolinium enhancement (LGE): Multifocal, mid-wall and subepicardial, in non-coronary distribution. Most common locations: basal interventricular septum, inferolateral wall, RV insertion points. Subendocardial LGE suggests ischemic etiology rather than CS. The “hook” or “step” pattern of basal septal mid-wall LGE is highly suggestive.
  • T2-weighted edema: Hyperintense myocardial signal indicates active inflammation; correlates with FDG-PET activity.
  • Wall motion and structural changes: Basal septal thinning, RV involvement (associated with worse prognosis), and segmental hypokinesis. RV ejection fraction less than 40% is an independent predictor of arrhythmia.
  • Quantitative tissue mapping: Native T1 mapping and extracellular volume fraction are emerging biomarkers that detect diffuse fibrosis missed by LGE alone.
  • LGE burden: Even modest LGE (>5% of LV mass) doubles the risk of major adverse cardiac events; LGE >20% is strongly predictive of mortality and arrhythmia.

FDG-PET: protocol matters

Standard oncologic FDG-PET preparation does NOT suppress physiologic myocardial glucose uptake and produces unreadable cardiac images. Dedicated cardiac sarcoidosis PET requires:

  1. Dietary preparation: 24 hours of high-fat, very-low-carbohydrate diet (less than 5 g carbohydrate per meal, no sugar, no juice) — shifts myocyte metabolism from glucose to free fatty acids.
  2. Prolonged fast: Greater than 12 hours fast prior to FDG injection (some protocols 18 hours).
  3. Optional unfractionated heparin loading: 50 U/kg IV 15 minutes before tracer to stimulate lipolysis and further suppress myocardial glucose uptake.
  4. Combined perfusion imaging: Rest perfusion (ammonia or rubidium PET, or SPECT myocardial perfusion) co-registered with FDG to distinguish active inflammation (perfusion-FDG mismatch) from chronic scar (matched defects) and from physiologic uptake (no perfusion abnormality).

Patterns: focal or focal-on-diffuse FDG uptake is suggestive of CS; diffuse uptake alone usually represents inadequate dietary preparation. Maximum standardized uptake value (SUVmax) and total inflammation burden quantify disease activity and track treatment response. Serial PET at 3 and 6 months after starting immunosuppression is the standard biomarker for adequate response.

CMR vs PET imaging Side-by-side comparison of cardiac MRI late gadolinium enhancement and FDG-PET focal uptake in cardiac sarcoidosis Cardiac MRI vs FDG-PET — Complementary Roles Cardiac MRI (LGE) What it shows: FIBROSIS Mid-wall basal septum LGE FDG-PET (after carb-restrict) What it shows: ACTIVE INFLAMMATION Focal-on-diffuse FDG uptake
CMR identifies fibrotic scar (chronic damage); FDG-PET identifies active granulomatous inflammation. Combined imaging maximizes diagnostic yield and guides treatment monitoring.
Cardiac Sarcoidosis — Procedure Steps Surgical stepper: Cardiac Sarcoidosis — Procedure Steps Cardiac Sarcoidosis — Procedure Steps 1 Diagnostic workup FDG-PET cardiac (rest myocardial suppression); cardiac MRI (LGE pattern, T2 edema); transthoracic ec 2 Steroid induction Prednisone 0.5-1 mg/kg/day (max 60mg) × 1-3 months → taper to maintenance 10-15mg over 6 months 3 Steroid-sparing Methotrexate 10-20 mg/wk OR mycophenolate 1g BID + low-dose prednisone (5-10mg) 4 Refractory disease Anti-TNF: infliximab 5 mg/kg IV at 0, 2, 6 wk → q8wk for refractory; rituximab in selected 5 Device therapy Permanent PPM for high-grade AV block; ICD: EF ≤35% OR scar+ AV block + indication; CRT for HF + LBB 6 Heart transplant For end-stage HF; recurrence in transplanted heart 5-10%; combined heart-lung if pulmonary sarcoid
Cardiac Sarcoidosis — Procedure Steps

S4. Endomyocardial Biopsy and Differential Diagnosis

Endomyocardial biopsy in cardiac sarcoidosis is limited by patchy granuloma distribution. Standard right ventricular biopsy yields non-caseating granuloma in only 20-25% of confirmed CS cases. Image-guided EMB targeting LGE-positive or PET-active regions can raise yield to 40-50%, particularly when guided by electroanatomic voltage mapping. Negative EMB does NOT exclude cardiac sarcoidosis.

When to pursue EMB

  • Isolated cardiac sarcoidosis without accessible extracardiac biopsy target
  • Suspected giant cell myocarditis (medical emergency requiring urgent diagnosis — multinucleated giant cells with myocyte necrosis differ histologically from sarcoid granulomas)
  • Atypical features prompting differential consideration: rapid LV dysfunction progression, refractory VT despite imaging-targeted therapy
  • Pre-transplant evaluation when histology is required by listing center

Critical differential diagnoses

ConditionDistinguishing featuresWhy it matters
Giant cell myocarditisRapidly progressive HF (weeks), multinucleated giant cells WITH myocyte necrosis (no granulomas), eosinophilic infiltrateMedian untreated survival 3 months; requires immediate combination immunosuppression (cyclosporine + steroid + azathioprine), often urgent transplant
Cardiac amyloidosis (ATTR or AL)Concentric LV thickening, low voltage on ECG, restrictive physiology, apical sparing on strain, positive PYP scan or biopsy with Congo red apple-green birefringenceDifferent therapy (tafamidis, daratumumab); steroids contraindicated for AL amyloid heart; CMR LGE diffuse subendocardial
Tuberculous myocarditisCaseating granulomas (CS is non-caseating), positive AFB stain, history of TB exposureSteroids can worsen TB; antituberculous therapy required first
Hypertrophic cardiomyopathy with VTAsymmetric septal hypertrophy, sarcomere mutation, family history, no granuloma on biopsyDifferent management; ICD on different criteria
Arrhythmogenic right ventricular cardiomyopathyRV dilation/dysfunction, fatty/fibrofatty replacement, desmosomal mutations, distinct ECG (epsilon wave, T wave inversion V1-V3)Genetic; family screening; sport restriction; different ICD criteria

How Experienced Clinicians prepare patients for FDG-PET in cardiac sarcoidosis

FDG-PET requires meticulous dietary preparation to suppress normal myocardial glucose uptake so that focal inflammation can be visualized. The standard protocol: 24-hour preparation period with high-fat, very-low-carbohydrate diet (think bacon, eggs, nuts, cheese — strictly no carbs), then 12-hour overnight fast before the scan. Some centers use intravenous heparin pre-scan to further shift cardiac metabolism away from glucose to free fatty acids. Improperly prepped PET shows diffuse myocardial uptake (false positive for “inflammation”) that is uninterpretable. Seasoned clinicians review the prep protocol with patients verbally AND give a written instruction sheet because the diet sounds counterintuitive; non-compliance ruins the study.

S5. Treatment: Immunosuppression and Device Therapy

Treatment combines anti-inflammatory therapy to suppress active granulomatous inflammation and device/medication therapy for the cardiac complications. Active inflammation on FDG-PET is the principal indication for immunosuppression; LGE without active uptake represents fibrotic scar that will not regress with steroid.

Glucocorticoid induction

PhaseRegimenDurationNotes
InductionPrednisone 0.5-1 mg/kg/d (typically 30-40 mg/d)1-3 monthsHigher doses for severe LV dysfunction, refractory arrhythmia, or extensive PET activity
TaperReduce by 5-10 mg every 2-4 weeksMonths 3-9Slower if symptoms recur or PET reactivates
MaintenancePrednisone 5-10 mg/d≥12 monthsContinued indefinitely in many patients with active disease; goal is lowest dose maintaining PET suppression

Steroid-sparing agents

  • Methotrexate: 10-15 mg PO weekly (max 25 mg) plus folic acid 1-5 mg daily. First-line steroid-sparing agent. Onset 2-3 months. Monitor CBC + LFT + creatinine monthly initially. Avoid in eGFR <50 and pregnancy.
  • Azathioprine: 1-2 mg/kg/d (target 100-150 mg/d). Check TPMT activity before initiation; severe deficiency contraindicates use. Onset 3-6 months. Alternative when MTX intolerant.
  • Mycophenolate mofetil: 1000-1500 mg PO BID. Reasonable alternative; less GI tolerability than MTX. Avoid in pregnancy.
  • Infliximab: 5 mg/kg IV at weeks 0, 2, 6, then q4-8 weeks. Reserved for refractory disease or where steroid + MTX inadequately suppress PET activity. Multidisciplinary review recommended; TB and HBV screening mandatory before initiation.
  • Hydroxychloroquine: 200-400 mg/d. Adjunct, not primary therapy; modest benefit in mild disease.

Heart failure and arrhythmia management

Standard HFrEF GDMT is applied: ACEi or ARNI (sacubitril/valsartan 24/26 mg PO BID titrated to 97/103 mg PO BID), beta-blocker (carvedilol 3.125 mg BID titrated to 25 mg BID), MRA (spironolactone 25 mg/d), and SGLT2 inhibitor (dapagliflozin 10 mg/d). Beta-blockers are particularly useful given high arrhythmia burden. Diuretics for congestion. CRT-D when LVEF less than 35% and QRS >130 ms with LBBB morphology persists despite GDMT plus immunosuppression.

For ventricular arrhythmias, antiarrhythmic options include amiodarone (loading 400 mg PO TID × 1-2 weeks then 200 mg/d) or sotalol (80 mg BID titrated, contraindicated in advanced LV dysfunction). VT ablation has lower long-term success in CS than ischemic VT (50-60% recurrence) due to evolving substrate, but is useful for refractory VT.

HRS 2014 ICD indications

ClassIndication
Class I (ICD recommended)Prior sustained VT/VF or cardiac arrest; LVEF ≤35% despite optimal therapy and immunosuppression; spontaneous sustained VT including treated VT; indication for permanent pacing in CS patient (ICD instead of PPM given arrhythmia risk)
Class IIa (ICD reasonable)LVEF 36-49% or RVEF <40% with myocardial scar on CMR or PET; syncope or near-syncope in CS; inducible sustained VT on EP study
Class IIb (may be considered)Pacing-dependent CS patient at low arrhythmia risk where pacemaker alone may be reasonable but uncertainty exists
Critical: ICD implantation in CS patients meeting Class I criteria should NOT be delayed pending response to immunosuppression. Active inflammation creates substrate for arrhythmia even before scar matures, and SCD risk persists during the months required for steroid response. Concomitant medical therapy and ICD are complementary.

S6. Monitoring, Prognosis, and Transplantation

Disease monitoring uses imaging biomarkers (FDG-PET SUVmax, total inflammation burden) every 3-6 months in the first 2 years, then annually if stable. CMR is repeated less frequently (annually or as clinically indicated) since LGE represents established fibrosis that does not regress. Echocardiography monitors LVEF and chamber size every 6-12 months.

Treatment response criteria

  • Complete response: Resolution of symptoms, normalization of LVEF, complete suppression of FDG-PET uptake, and decrease in arrhythmia burden
  • Partial response: Improvement in any of these parameters without complete normalization
  • Stable disease: No worsening on serial imaging, despite incomplete response
  • Disease progression: New LGE, increased PET uptake, declining LVEF, or new arrhythmia despite therapy

Prognostic factors

FactorImpact on 5-year survival
Preserved LVEF (≥50%) at presentation, no VT85-90%
LVEF 35-49% with response to therapy75-85%
NYHA II symptoms, partial response to therapy65-75%
LVEF <35%, sustained VT, NYHA III-IV at presentation50-60%
RV ejection fraction <40% with biventricular dysfunction40-55%

Heart transplantation

End-stage cardiac sarcoidosis with refractory heart failure or refractory ventricular arrhythmias despite maximal therapy is an indication for orthotopic heart transplantation. Post-transplant outcomes match those of other indications: 1-year survival approximately 85-90%, 5-year survival 70-75%. Sarcoid recurrence in the allograft is uncommon (less than 5%) on standard maintenance immunosuppression. Mechanical circulatory support (LVAD) bridges to transplant for patients in refractory cardiogenic shock.

Pearl: Multidisciplinary cardiac sarcoidosis clinics combining cardiology, electrophysiology, advanced HF, pulmonology, and rheumatology improve diagnostic accuracy and treatment outcomes. These centers also coordinate the dedicated cardiac sarcoid PET protocol that requires both cardiology imaging expertise and proper dietary preparation supervision.
Pitfall: Treating LGE without active PET inflammation is futile and exposes patients to steroid toxicity. Established fibrosis does not regress with immunosuppression. Reserve treatment for patients with active inflammation on PET or new clinical/imaging worsening; quiescent disease can be monitored without active immunosuppression.

S7. Practice Insights: Bedside Notes on Cardiac Sarcoidosis

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A pacemaker fixes the rhythm and ends the investigation, while the granulomas that caused the block keep spreading through myocardium; no wonder this disease is THE most under-recognized cause of AV block in patients under 60. In experienced hands the pivot points are sending any unexplained AV block under 60 to cardiac MRI + FDG-PET, applying HRS 2014 criteria thoroughly, and using combination immunosuppression (prednisone + steroid-sparing) early rather than steroid monotherapy. Experienced practice tracks three things every visit: cardiac MRI scar burden, FDG-PET activity, and BNP/clinical HF symptoms.

What the Guideline Misses — AV Block Under 60 = Cardiac Sarcoid Workup

Unexplained AV block (Mobitz II or complete) in a patient under 60 has cardiac sarcoidosis prevalence of 25-35%. In experienced practice every young AV block patient gets cardiac MRI with late gadolinium enhancement + FDG-PET BEFORE permanent pacemaker. The diagnostic window for catching active inflammation matters — pacemaker first, then “incidentally” find sarcoid later means worse outcomes than treating inflammation early.

Patterns Experienced Clinicians Have Seen Repeat — Cardiac MRI + FDG-PET Combination

Cardiac MRI shows fibrosis (late gadolinium enhancement, scar pattern). FDG-PET (with proper dietary preparation — 24h high-fat low-carb prep, 12h fast) shows ACTIVE inflammation. The two together are the diagnostic gold standard for cardiac sarcoidosis — scar with active inflammation = treat. Scar without active inflammation = monitor + pacemaker/ICD as appropriate. About 1 in 5 of the cardiac MRI-positive patients have no PET activity = burnt-out disease.

Combination Immunosuppression Strategy

Prednisone monotherapy 30-40 mg/day works initially but recurrence rate on taper is high (40-50%). Experienced practice adds steroid-sparing (methotrexate 10-20 mg/wk OR mycophenolate 1-1.5 g BID) from induction, allowing faster prednisone taper. Infliximab/adalimumab for refractory cases. Treat duration is 12-24 months typically; re-image at 6 months to assess activity reduction.

Bedside Heuristic — ICD for High-Risk Phenotypes

HRS 2017 + 2024 ICD indications in cardiac sarcoid: severe LV dysfunction (EF <35%), sustained VT/VF, syncope with extensive scar on MRI, EP-induced VT. In practice experienced practitioners assess all newly diagnosed cardiac sarcoid for ICD candidacy with EP study and cardiac MRI. About half of the patients get ICD — primary prevention reduces SCD risk in this population.

A Case That Reframed the established Approach — AV Block in a Marathon Runner

A man in his late 40s, marathon runner, presented with syncope during a race. ECG: complete heart block. No structural HD on initial echo. Outside cardiology was about to place permanent pacemaker. The treating clinicians requested cardiac MRI + FDG-PET first: MRI showed patchy mid-myocardial late gadolinium enhancement of basal septum and lateral wall; FDG-PET showed corresponding active inflammation. CT chest: mediastinal lymphadenopathy. Mediastinal LN biopsy: non-caseating granulomas. Diagnosis: cardiac sarcoidosis with secondary pulmonary involvement. Started prednisone 40 mg + methotrexate 15 mg/wk; ICD placed (not just pacemaker) due to scar burden. At 18 months: MRI scar stable, PET-negative, no further arrhythmias. What experienced clinicians learned: AV block + young patient + athletic = cardiac sarcoid workup BEFORE PPM. The biopsy site outside the heart (mediastinal LN) often confirms — biopsy goes where the lymphadenopathy is.

Bedside lesson: unexplained AV block in patient under 60 = cardiac MRI + FDG-PET + CT chest for mediastinal LN biopsy BEFORE permanent pacemaker. Cardiac sarcoid prevalence 25-35% in this group.

Practice Pattern Refinements That Diverge From Standard Guidelines

  1. Cardiac MRI + FDG-PET for every unexplained AV block under 60 BEFORE permanent pacemaker. Cardiac sarcoid prevalence 25-35% in this group. Treating active inflammation early changes trajectory.
  2. Combination immunosuppression at induction, not after prednisone fails. Prednisone 30-40 mg + MTX 10-20 mg/wk OR MMF 1-1.5 g BID from start. Reduces recurrence on taper.
  3. FDG-PET dietary prep is critical. 24h high-fat low-carb diet + 12h fast suppresses normal myocardial glucose uptake, allowing inflammation visualization. Improperly prepped PET = uninterpretable.
  4. ICD candidacy assessment for every cardiac sarcoid at diagnosis. Extensive scar on MRI + EF <35% + syncope = ICD primary prevention. EP study for ambiguous cases. About half of the patients get ICDs.
Cardiac Sarcoidosis Algorithm — AV Block Trigger, MRI+PET, Combination IS AV block <60 → cardiac MRI + FDG-PET → HRS criteria → immunosuppression + ICD if indicated Cardiac Sarcoidosis Algorithm — AV Block Trigger, MRI+PET, Combination IS Unexplained AV block <60 OR VT/CHF + family hx sarcoid CARDIAC MRI + FDG-PET BEFORE PERMANENT PACEMAKER MRI: late gadolinium (scar) + PET: 24h diet prep (suppress normal uptake) → active inflammation HRS 2014 criteria + extra-cardiac biopsy Mediastinal LN if accessible (higher yield than EMB) Immunosuppression (combination) Pred 30-40 mg/d + MTX 10-20/wk OR MMF 1-1.5 g BID Infliximab for refractory 12-24 months total Device therapy Pacemaker for AV block ICD if EF <35% or VT or extensive scar + syncope EP study if ambiguous Re-image at 6 months: FDG-PET activity reduction confirms response; cardiac MRI for scar stability Multidisciplinary follow-up (cardiology + pulmonology + rheumatology) Observed: cardiac sarcoid 25-35% prevalence in young AV block. MRI+PET before PPM. — gomdori, MD

Frequently Asked Questions

Suspect cardiac sarcoidosis in patients younger than 60 years presenting with unexplained high-grade AV block, sustained ventricular tachycardia, or non-ischemic cardiomyopathy, particularly when there is a history of pulmonary or extracardiac sarcoidosis. Up to 30 percent of biopsy-proven systemic sarcoidosis patients have cardiac involvement on advanced imaging, but only 5 percent are clinically apparent. The triad of conduction disease, ventricular arrhythmia, and segmental wall motion abnormality with thinned basal septum is the classic presentation.
Cardiac MRI with late gadolinium enhancement detects fibrosis (typically multifocal mid-wall and subepicardial in non-coronary distribution, often basal septum or inferolateral wall) and is highly sensitive. FDG-PET with dedicated cardiac sarcoidosis protocol (greater than 12 hours fast, very low carbohydrate diet, optional unfractionated heparin loading) detects active inflammation as focal or focal-on-diffuse uptake; combined CMR plus PET maximizes sensitivity and specificity. Endomyocardial biopsy yield is low (20-30 percent) due to patchy granuloma distribution, even when image-guided.
Prednisone 0.5 to 1 mg/kg per day (typically 30-40 mg/d) for 1-3 months, then taper over 6-12 months to a maintenance dose of 5-10 mg/d. Methotrexate 10-15 mg/week or azathioprine 2 mg/kg/d is added as steroid-sparing agent for refractory disease, intolerable steroid side effects, or planned long-term therapy. Infliximab 5 mg/kg every 4-8 weeks is reserved for refractory cases after multidisciplinary discussion. Treatment response is monitored by serial FDG-PET (typically at 3-6 months), with reduction in maximum standardized uptake value indicating successful inflammation control.
Class I indications per HRS 2014 include prior sustained VT/VF or cardiac arrest, LVEF less than 35 percent despite optimal therapy, and indication for permanent pacing in any cardiac sarcoidosis patient (cardiomyopathy progression risk justifies ICD over standard pacemaker). Class IIa indications include LVEF 36-49 percent or RV ejection fraction less than 40 percent with myocardial scar on CMR or PET, syncope or near-syncope, and inducible sustained VT on electrophysiology study. ICD implantation should not be delayed for response to immunosuppression in patients meeting Class I criteria.
Five-year survival with timely diagnosis and treatment is approximately 75-90 percent, but drops to 60-70 percent with advanced LV dysfunction at presentation. The strongest negative predictors are LVEF less than 35 percent, sustained VT, NYHA class III-IV symptoms, and persistent FDG-PET activity despite treatment. Heart transplantation provides excellent post-transplant survival comparable to other indications, with low risk of allograft sarcoid recurrence (less than 5 percent) on standard maintenance immunosuppression.

Leave a Reply

Your email address will not be published. Required fields are marked *